Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR

@article{Ohji2020EfficacyAS,
  title={Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR},
  author={M. Ohji and Kanji Takahashi and A. Okada and Masato Kobayashi and Y. Matsuda and Yasuhiro Terano and Masahito Tsukasa Tatsushi Takeya Hirokuni Shinpei Kanji Ryo Ohji Hanemoto Kaga Kouno Kitamei Sato Takahashi Ya and T. Hanemoto and T. Kaga and Takeya Kouno and H. Kitamei and Shin'pei Sato and R. Yanai and E. Uchio and K. Miyata and Y. Wakabayashi and T. Maeno and T. Yasukawa and M. Horiguchi and T. Nishimura and A. Kawahara and Y. Kurimoto and Ken-ichi Murai and Namie Kobayashi and W. Kimura and Eriko Matsushita and T. Iida and K. Yasuda and Y. Kato and M. Miura and R. Mori and Atsushi Sugiyama and Yasuo Ito and D. Kimura and K. Nakai and C. Matsumoto and S. Takeuchi and K. Okoshi and Y. Nuno and Y. Nomoto and Toshio Mori and M. Takeda and N. Yoshida and M. Hosokawa and K. Sonoda},
  journal={Advances in Therapy},
  year={2020},
  volume={37},
  pages={1173 - 1187}
}
Purpose To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD). Methods Adults aged at least 50 years old with exudative AMD and best-corrected visual acuity (BCVA) of 73–25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were included. Patients received three monthly doses of IVT-AFL 2 mg. At week 16, patients were randomized 1:1 to… Expand

Figures and Tables from this paper

...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
...
1
2
3
4
...